

## 04 January 2021

	Close price at 31-Dec-2020	Weekly % change	Month to date	Year to date	Last 12 months
<b>FTSE/JSE indices</b>					
All-Share Index	59,408.68	0.4%	4.1%	4.1%	4.1%
All-Share Index Total Return	9,266.78	0.4%	4.2%	7.0%	7.0%
Resources Index	33,100.33	0.8%	9.5%	16.9%	16.9%
Industrials Index	82,676.35	0.4%	-1.2%	10.2%	10.2%
Financials Index	30,301.87	-0.4%	8.0%	-23.0%	-23.0%
Top 40 Index	54,379.58	0.5%	3.8%	7.0%	7.0%
Shareholder Weighted Index	21,775.25	0.6%	4.0%	2.6%	2.6%
Capped Shareholder Weighted Index	23,184.88	0.6%	5.5%	0.6%	0.6%
SA Listed Property Index	1,229.58	-0.8%	13.7%	-34.5%	-34.5%
SA Volatility Index	18.44	-1.3%	-10.0%	16.6%	16.6%
<b>Interest-bearing indices</b>					
FTSE/JSE All Bond Index (Albi)	758.96	-0.1%	2.4%	8.7%	8.7%
StefI Composite Index	464.58	0.1%	0.3%	5.4%	5.4%
FTSE/JSE Inflation-Linked Index	268.04	-0.9%	2.3%	3.9%	3.9%
<b>Interest rates</b>					
Prime rate	7.00%			-30.0%	-30.0%
Repo rate	3.50%			-46.2%	-46.2%
<b>Commodities (in US dollars)</b>					
Gold price	1,894.23	0.8%	6.6%	24.3%	24.3%
Platinum price	1,069.93	4.4%	11.5%	10.1%	10.1%
Oil price	51.80	1.0%	8.2%	-21.7%	-21.7%
<b>Global indices (in base currency)</b>					
Dow Jones (US)	30,606.48	1.3%	3.3%	7.2%	7.2%
S&P 500 (US)	3,756.07	1.4%	3.7%	16.3%	16.3%
FTSE (UK)	3,673.63	-0.5%	3.7%	-12.5%	-12.5%
Hang Seng (Hong Kong)	27,231.13	3.2%	3.4%	-3.4%	-3.4%
Shanghai	3,473.07	3.3%	2.4%	13.9%	13.9%
Nikkei (Japan)	27,444.17	2.9%	3.8%	16.0%	16.0%
Cac 40 (France)	5,551.41	0.5%	0.6%	-7.1%	-7.1%
Dax (Germany)	1,297.81	1.1%	4.0%	4.8%	4.8%
MSCI Emerging	1,291.26	3.0%	7.2%	15.8%	15.8%
MSCI Developed	2,690.04	1.2%	4.1%	14.1%	14.1%
US Volatility Index	22.75	5.7%	10.6%	65.1%	65.1%
<b>Exchange rates</b>					
Rand/US dollar	14.69	-0.3%	5.3%	-4.7%	-4.7%
Rand/euro	17.95	-0.7%	2.8%	-12.6%	-12.6%
Rand/pound	20.08	-1.4%	2.6%	-7.6%	-7.6%
Dollar/euro	1.22	-0.3%	-2.4%	-8.2%	-8.2%
<b>Inflation indicator</b>					
CPI					3.2%
<b>Group indicator</b>					
Momentum Metropolitan Holdings	15.76	1.2%	1.2%	-27.8%	-27.8%

\*Last available numbers used, as these numbers were not available

### Global update

London — Britain's exit from the EU's single market is expected to cause significant disruption and cost. Yet the upheaval is also supposed to yield opportunity. The case for Brexit, which convinced a majority of voters in the 2016 referendum and helped Prime Minister Boris Johnson win power, leaned heavily on the purported long-term benefits of being outside the now 27-member EU.

Moscow — Russia is accusing the West of maligning its achievements in the global race to defeat Covid-19 as its attempts to win key markets for its Sputnik V vaccine run up against the demands of regulators.

### Local update

The JSE and the rand advanced as a Covid-19 vaccine developed by AstraZeneca and the University of Oxford became the second coronavirus shot to be approved in the UK, boosting investor sentiment that had waned in recent weeks due to surging infections worldwide. The JSE closed within 400 points of the psychologically important 60,000 level while the rand regained positive momentum after the UK said it would begin administering the new vaccine as early as today. People that will get priority include those over 80, care-home residents and healthcare workers.

Fuel and chemicals giant Sasol's sale of assets to rein in debt took another step forward with the finalisation of its \$404m (R5.9bn) disposal of its stake in the US-based Gemini polythene business. Sasol, which recently said it had raised \$3bn, or nearly R44bn, from asset sales — the biggest being the \$2bn divestment from its Lake Charles chemical project in the US — has flagged the possibility of a rights issue to reduce debt.

World number three gold miner AngloGold Ashanti has finalised the sale of its stake in the Sadiola gold mine in Mali for nearly R400m as it completes its asset disposal programme. JSE-listed AngloGold, which this year sold all its SA mines and assets to Harmony Gold, agreed with its partner, Canada's Iamgold, to sell the Sadiola mine.

Health minister Zweli Mkhize, top officials and advisers said at a briefing on Sunday evening that they were engaged in intense negotiations to gain access to a Covid-19 vaccine for priority individuals as early as February, but made clear that there were no agreements yet in place with any pharmaceutical companies. The government also made clear that it will procure all Covid-19 vaccines itself for distribution and that private sector organisations or medical schemes will not be permitted to procure independently for their own members. Medical aid scheme members and the private sector will cross-subsidise the public sector.